The prognostic value of decreased miR-101 in various cancers: a meta-analysis of 12 studies

Abstract

BackgroundA consensus regarding the prognostic value of decreased miR-101 in human cancers has not been reached. This study aimed to comprehensively investigate the internal associations between loss of miR-101 expression and prognostic implications in patients with cancer.Materials and methodsAll relevant literature in electronic databases, including PubMed, ISI Web of Science, and Embase, up to March 1, 2017 were searched. Correlations between decreased miR-101 and clinicopathological parameters were defined by odds ratios (ORs). The degree of association between reduced miR-101 and survival outcome was evaluated by pooled hazard ratios (HRs) and relevant 95% CIs.ResultsTwelve eligible studies with 2,088 patients were included in this meta-analysis. Decreased miR-101 expression was closely connected with poor overall survival, with a pooled HR of 2.15 (95% CI 1.71–2.7, P<0.001). This correlation was also revealed when stratified analysis was conducted with respect to ethnicity, cancer type, sample size, specimen source, and analysis model. However, decreased miR-101 was not associated with disease-free survival, recurrence-free survival, or progression-free survival, with a pooled HR of 1.59 (95% CI 0.83–3.03, P=0.128), despite a positive trend. In addition, reduced miR-101 was intimately related to poorer tumor differentiation (OR 2.17, 95% CI 1.14–4.13; P=0.019), advanced tumor classification (OR 5.25, 95% CI 3.39–8.12; P<0.001), and higher TNM stage (OR 6.18, 95% CI 3.79–10.09; P<0.001).ConclusionOur findings suggest that loss of miR-101 expression is correlated with worse overall survival in a variety of cancers, and could serve as a predictive indicator for clinicopathological features. Furthermore, miR-101 may become a feasible therapeutic target in most human cancers.

mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance

“…Recently, miR-101-3p has been reported as a potent tumor suppressor in cancer development, progression, and therapy because it enhances doxorubicin-induced cytotoxicity and impacts upon chemoresistance of cisplatin in HepG2 cells [40,41,42]. According to our results, miR-101 downregulation was previously observed in multiple cancerous tissues, such as lung, colon, liver, gastric, breast, ovary, and prostate [25,43,44,45,46] decreasing early when tumors are poorly differentiated. Nonetheless, Li et al [25] analyzed the data from The Cancer Genome Atlas (TCGA) and demonstrated that miR-101-1 expression was lower in cancer than in non-tumor liver tissues, and that this downregulation was also closely related to poor differentiation; high tumor, node, and metastasis (TNM) classification; poor tumor stage; positive lymph node metastasis; high alpha-fetoprotein; and poor overall survival in patients [47], assuming a great diagnostic and prognostic value of HCC [25].…”

miRNA expression profiles in liver grafts of HCV and HIV/HCV‐infected recipients, 6 months after liver transplantation

“… 18 For example, the downregulation of miR‐101 seems to be implicated in the proliferation, apoptosis, angiogenesis, drug resistance, invasion, and metastasis of HCC, gastric cancer, intrahepatic cholangiocarcinoma, osteosarcoma, non‐small‐cell lung cancer, oral squamous cell carcinoma, bladder transitional cell carcinoma, cervical cancer, intraductal and ERα‐positive breast cancer. 29 , 30 Moreover, several studies have shown its prognostic value not only in terms of correlation with clinicopathological features of the tumors but also in terms of prediction of patient overall survival and risk of tumor recurrence. 31 miR‐122 has been investigated as a biomarker of drug‐induced liver injury 31 as well as endometriosis, 32 metabolic syndromes, and type 2 diabetes.…”

Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA‑gene pairs in small‑cell lung cancer

“…A basic study revealed that miR-101 could directly inhibit the overexpression of EZH2 in lung cancer cells, and cooperate with paclitaxel to induce apoptosis, and inhibit invasion and cell proliferation (38). In addition, a meta-analysis of 2,088 tumor patients revealed that the low expression of miR-101 predicted poor overall survival and could be used as a predictive indicator for clinicopathological features (39). KIF11, also known as Eg5, is a homotetramer of BimC in kinesin family 5, whose overexpression leads to spindle defects and genetic instability, affecting cell division and proliferation, and is associated with tumor invasion, metastasis, recurrence and prognosis (40,41).…”